Summary:
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem™ in subjects with mild dementia due to Alzheimer's Disease.
Qualified Participants Must:
• Be 50 years of age or older
•
Have mild dementia due to probable AD
• Have the availability of a study partner
Qualified Participants May Receive:
May be compensated for time and travel.